News
Merck, the New Jersey-based drug giant, is spending $1 billion on a new Delaware factory to bring production of its ...
Merck has initiated construction of a $1 billion, 470,000-square-foot biologics center of excellence in Wilmington, Delaware.
It will build a Wilmington, Delaware facility dedicated to making its cancer drug, Keytruda, for U.S. patients.
U.S. drugmaker Merck said on Tuesday it is investing $1 billion in a new Delaware plant to expand domestic production as it ...
Located at Chestnut Run Innovation & Science Park, the Merck Wilmington Biotech project will comprise laboratory, ...
According to Merck, the total investment is now expected to be over $1 billion, with 500 full-time jobs and 4,000 ...
The firm reported revenues of $15.53 billion and adjusted earnings per share of $2.22, surpassing consensus predictions of ...
Merck CEO Robert Davis spoke about the new state-of-the-art biologics center slated to be based in Wilmington, Delaware that ...
Merck announced on Tuesday that it is investing $1 billion in a new Delaware plant to expand domestic production as it ...
The Delaware facility will ensure a domestic supply of biologic drugs including the cancer drug Keytruda.
Merck KGaA struck a $3.9 billion deal for SpringWorks Therapeutics. Novartis plans to acquire Regulus Therapeutics for $800 ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback